Remedy Plan Rockets Innovation with $18M Funding to Advance Tunable NAMPT Inhibitors

Remedy Plan Therapeutics is thrilled to announce a successful funding round, raising $18 million to accelerate its pioneering approach to small molecule therapeutics. Focused on transforming the field of NAMPT inhibition, this innovative start-up employs a groundbreaking mechanism that allows for hyperbolic, highly tunable inhibition of NAMPT—achieving effective modulation without the severe on-target toxicity traditionally associated with such treatments. This significant financial milestone not only underscores investor confidence in Remedy Plan’s novel approach but also empowers the company to further advance its robust pipeline of tunable NAMPT inhibitors. Designed to address a spectrum of conditions ranging from solid tumors and hematologic malignancies to obesity and autoimmune disorders, Remedy Plan’s portfolio is strategically positioned to meet some of the most pressing medical challenges of our time. At the heart of this transformative pipeline is RPT1G, Remedy Plan’s lead asset, which has demonstrated a favorable efficacy and tolerability profile in preclinical studies. The promising data has paved the way for RPT1G’s anticipated entry into the clinic in 2024, marking an important milestone in the journey toward delivering safer, more effective therapies for patients facing diseases driven by NAMPT dysregulation. With the newly secured funding, the company is set to expand its research capabilities, enhance clinical development efforts, and explore further opportunities within the therapeutic landscape. By continuing to push the boundaries of scientific discovery, Remedy Plan Therapeutics is committed to redefining treatment options and opening doors to new therapeutic possibilities for patients worldwide.